Introduction
============

Renal cell carcinoma (RCC) is a disease in which cells in the kidney tubules undergo oncogenic transformation. RCC has multiple subtypes and may occur in hereditary (2--3% of RCC) or sporadic forms ([@b1-ijo-48-05-1837],[@b2-ijo-48-05-1837]). RCC is the third most common urological cancer and accounts for 3% of all adult neoplasias. Clear cell RCC (ccRCC) is the most common subtype of sporadic RCC (\~80%) ([@b1-ijo-48-05-1837]). The standard curative treatment for localized diseases remains surgical excision with total nephrectomy. In contrast, at diagnosis, \~30% of RCCs have already metastasized. The 5-year survival rate in patients with advanced stage RCC is poor (5--10%) due to recurrence or distant metastasis ([@b3-ijo-48-05-1837],[@b4-ijo-48-05-1837]). Recent molecularly targeted therapy has improved the survival rate of patients with advanced RCC ([@b5-ijo-48-05-1837],[@b6-ijo-48-05-1837]). However, almost all patients eventually relapse or show distant metastasis due to acquired resistance to molecularly targeted therapy. Identifying molecular pathways responsible for RCC metastasis could provide novel approaches for the development of therapies that block the RCC metastatic pathways.

The discovery of microRNA (miRNA) in the human genome provided new directions in cancer research. The miRNAs are endogenous small RNA molecules (19--22 bases long) that regulate protein coding gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner ([@b7-ijo-48-05-1837],[@b8-ijo-48-05-1837]). Numerous studies have shown that miRNAs are aberrantly expressed in many human cancers, and they have significant roles in the initiation, development and metastasis of those cancers ([@b9-ijo-48-05-1837]--[@b11-ijo-48-05-1837]). Moreover, normal regulatory mechanisms can be disrupted by the aberrant expression of tumor-suppressive or oncogenic miRNAs in cancer cells. Therefore, identifying aberrantly expressed miRNAs is an important first step toward elucidating miRNA-mediated oncogenic pathways.

Using miRNA expression signatures, we have identified molecular pathways in RCC that are mediated by aberrantly expressed miRNAs ([@b12-ijo-48-05-1837]--[@b15-ijo-48-05-1837]). For example, downregulation of tumor-suppressive miR-218 promoted cancer cell migration and invasion through dysregulation of the focal adhesion pathway. In this regard, caveolin-2 has an oncogenic function in RCC cells ([@b13-ijo-48-05-1837]). The epithelial-mesenchymal transition (EMT)-related *miR-200* family (*miR-200a/b/c*, *miR-141* and *miR-429*) is significantly downregulated in RCC where they act as tumor suppressors that target the focal adhesion and ErbB signaling pathways ([@b14-ijo-48-05-1837]). The *miR-143/145* cluster was frequently reduced in RCC tissues; restoration of these miRNAs significantly inhibited RCC cell proliferation and invasion through targeting of hexokinase-2 ([@b16-ijo-48-05-1837]). More recently, expression of the *miR-23b/27b* cluster was significantly decreased in ccRCC tissues and associated with pathological grade and stage of the disease ([@b17-ijo-48-05-1837]).

Our miRNA expression signatures of human cancers revealed that *miR-26a* and *miR-26b* were frequently downregulated in various types of cancer tissues ([@b10-ijo-48-05-1837],[@b18-ijo-48-05-1837],[@b19-ijo-48-05-1837]), suggesting that these miRNAs act as tumor suppressors targeting several oncogenic pathways. Database searches revealed that there were few reports of functional analyses of *miR-26a* or *miR-26b* in RCC. The aim of the present study was to investigate the functional significance of *miR-26a* and *miR-26b* and to identify molecular targets and pathways contributing to metastasis in RCC cells by *miR-26a* or *miR-26b* regulation. We expect that this analysis will provide important insights into the potential molecular mechanisms of RCC oncogenesis and metastasis and will facilitate the development of therapeutic strategies for the treatment of the disease.

Materials and methods
=====================

RCC clinical specimens and cell culture
---------------------------------------

A total of 15 pairs of ccRCC specimens and corresponding non-cancerous specimens were collected from patients who had undergone radical nephrectomy at Chiba University Hospital (Chiba, Japan) from 2012 to 2015. These specimens were staged according to the General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma based on the American Joint Committee on Cancer (AJCC)-UICC TNM classification. The clinicopathological characteristics of the patients are summarized in [Table I](#tI-ijo-48-05-1837){ref-type="table"}. Before tissue collection, written informed consent of tissue donation for research purposes was obtained from all the patients.

We used two human RCC cell lines (786-O and A498) obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) as previously described ([@b12-ijo-48-05-1837]--[@b14-ijo-48-05-1837]).

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)
--------------------------------------------------------------------------------

The procedure for PCR quantification was previously described. TaqMan probes and primers for *LOXL2* (P/N: Hs00158757_ml; Applied Biosystems, Foster City, CA, USA), *PLOD2* (P/N: Hs01118190_ml; Applied Biosystems) and *GUSB* (the internal control; P/N: Hs00939627_ml; Applied Biosystems) were assay-on-demand gene expression products. The expression levels of *miR-26a* (assay ID: 000405; Applied Biosystems) and *miR-26b* (assay ID: 000407; Applied Biosystems) were analyzed by TaqMan quantitative real-time RT-PCR (TaqMan MicroRNA assay; Applied Biosystems) and normalized to the expression of RNU48 as previously described ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837],[@b21-ijo-48-05-1837]).

Transfection with mature miRNAs and siRNAs
------------------------------------------

The following mature miRNAs were used: Ambion Pre-miR miRNA precursor for *hsa-miR-26a-5p* (product ID: PM10249; Applied Biosystems) and for *hsa-miR-26b-5p* (product ID: PM12899; Applied Biosystems). The following siRNAs were used: Stealth Select RNAi si-RNA, *si-PLOD2* (cat nos. HSS108124 and HSS182371; Invitrogen) and negative control miRNA/siRNA (P/N: AM17111; Applied Biosystems). RNAs were incubated with Opti-MEM (Invitrogen) and Lipofectamine RNAiMax transfection reagent (Invitrogen) as previously described ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837],[@b21-ijo-48-05-1837]).

Cell proliferation, migration and invasion assays
-------------------------------------------------

786-O and A498 cells were transfected with 10 nM miRNAs or si-RNAs by reverse transfection. Cell proliferation, migration and invasion assays were performed as previously described ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837],[@b21-ijo-48-05-1837]).

Western blotting
----------------

Cells were harvested 72 h after transfection, and lysates were prepared. Protein lysates (20 μg) were separated on Mini-PROTEAN TGX gels (Bio-Rad Laboratories, Hercules, CA, USA) and transferred to PVDF membranes. Immunoblotting was performed with rabbit anti-LOXL2 antibodies (1:1000; ab96233; Abcam, Cambridge, UK) and rabbit anti-PLOD2 antibodies (1:300; 21214-1-AP; Proteintech Group, Inc., Chicago, IL, USA). Anti-GAPDH antibodies (1:1,000; ab8245; Abcam) were used as an internal loading control. The membranes were washed and incubated with anti-rabbit IgG horseradish peroxidase (HRP)-linked antibodies (\#7074; Cell Signaling Technology). Complexes were visualized with Clarity Western Substrate (Bio-Rad Laboratories).

Screening of miR-26a and miR-26b target genes using in silico analysis and gene expression data
-----------------------------------------------------------------------------------------------

To identify *miR-26a/b* target genes, we used *in silico* analysis and genome-wide gene expression analysis. First, we screened genes using TargetScan release 6.2 (<http://www.targetscan.org/>). Next, to identify upregulated genes in ccRCC clinical specimens, we analyzed publicly available gene expression profiles in the GEO database (accession nos. GSE22541 and GSE36895). Our strategies for miRNA target screening were previously described ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837],[@b21-ijo-48-05-1837]).

Plasmid construction and dual-luciferase reporter assay
-------------------------------------------------------

Partial wild-type sequences of the *LOXL2* and *PLOD2* 3′-untranslated region (UTR) or those with deleted *miR-26a/b* binding sites were inserted between the *Xho*I-*Pme*I restriction sites in the 3′-UTR of the *hRluc* gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The procedure for the dual-luciferase reporter assay was previously described ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837],[@b21-ijo-48-05-1837]).

Statistical analysis
--------------------

The relationships between the two groups and the numerical values obtained by real-time RT-PCR were analyzed using the Mann-Whitney U-test. The relationships among the three variables and numerical values were analyzed using the Bonferroni-adjusted Mann-Whitney U test. Spearman\'s rank test was used to evaluate the correlations between the expression of (*miR-26a* and *LOXL2*), (*miR-26a* and *PLOD2*), (*miR-26b* and *LOXL2*) and (*miR-26b* and *PLOD2*). All analyses were performed using Expert StatView (version 5; SAS Institute, Inc., Cary, NC, USA).

Results
=======

Expression levels of miR-26a and miR-26b in ccRCC clinical specimens and cell lines
-----------------------------------------------------------------------------------

The expression levels of *miR-26a* and *miR-26b* were significantly lower in ccRCC specimens than in corresponding non-cancerous specimens (P=0.0171 and P=0.0136, respectively; [Fig. 1A and B](#f1-ijo-48-05-1837){ref-type="fig"}). In 786-O and A498 cells, the expression levels of *miR-26a* or *miR-26b* were lower than in non-cancerous specimens.

Effects of miR-26a and miR-26b restoration on cell proliferation, migration and invasion activities in ccRCC cells
------------------------------------------------------------------------------------------------------------------

To investigate the functional effects of *miR-26a* or *miR-26b*, we performed gain-of-function studies using mature miRNA transfection of 786-O and A498 cells.

The XTT assays demonstrated that cell proliferation was not inhibited in *miR-26a* or *miR-26b* transfectants in comparison with the mock or miR-control transfectants ([Fig. 1C](#f1-ijo-48-05-1837){ref-type="fig"}).

In contrast, the migration assays demonstrated that cell migration activity was significantly inhibited in *miR-26a* or *miR-26b* transfectant cells in comparison with the mock or miR-control transfectants ([Fig. 1D](#f1-ijo-48-05-1837){ref-type="fig"}). The Matrigel invasion assays demonstrated that cell invasion activity was significantly inhibited in *miR-26a* or *miR-26b* transfectant cells in comparison with the mock or miR-control transfectants ([Fig. 1E](#f1-ijo-48-05-1837){ref-type="fig"}).

Identification of candidate target genes of miR-26a and miR-26b in ccRCC cells
------------------------------------------------------------------------------

To identify target genes of *miR-26a* and *miR-26b* (the seed sequences of the two miRNAs are identical), we used *in silico* analysis and genome-wide gene expression data. First, we searched the TargetScan database (release 6.2: <http://www.targetscan.org/>) and identified 3,419 genes that had putative target sites for *miR-26a* and *miR-26b* in their 3′-UTRs. Next, we pared down the list of putative candidate genes based on upregulated genes determined by the gene expression data set of RCC clinical specimens in the GEO (Gene Expression Omnibus) database (accession numbers: GSE36895, GSE22541). The flow chart outlining our strategy for identification of candidate target genes of *miR-26a* and *miR-26b* is shown in [Fig. 2](#f2-ijo-48-05-1837){ref-type="fig"}.

From this selection, 39 candidate genes were identified as targets of *miR-26a* and *miR-26b* ([Table II](#tII-ijo-48-05-1837){ref-type="table"}). Among these candidate genes, we focused on *LOXL2* and *PLOD2* genes because these genes have two conserved target sites for *miR-26a* and *miR-26b* in their 3′-UTRs, and function as collagen cross-linking enzymes associated with extracellular matrix (ECM) stiffness. Recent studies showed that aberrantly expressed ECM contributes to cancer cell metastasis ([@b22-ijo-48-05-1837],[@b23-ijo-48-05-1837]). Therefore, these two genes were chosen for further analysis.

Direct regulation of LOXL2 and PLOD2 by miR-26a and miR-26b in ccRCC cells
--------------------------------------------------------------------------

We first performed qRT-PCR and Western blotting to investigate whether expression of the *LOXL2* gene and protein were reduced by restoration of *miR-26a* or *miR-26b* in 786-O and A498 cells. We found that the mRNA and protein expression levels of *LOXL2*/LOXL2 were significantly repressed in *miR-26a* or *miR-26b* transfectant cells in comparison with mock or miR-control transfectants ([Fig. 3A and B](#f3-ijo-48-05-1837){ref-type="fig"}).

Next, to investigate whether *LOXL2* mRNA had target sites for *miR-26a* or *miR-26b*, we performed luciferase reporter assays in 786-O cells. We used vectors encoding either the partial wild-type sequence of the 3′-UTR of *LOXL2*, including the predicted *miR-26a/b* target sites, or deletion vectors lacking the *miR-26a/b* target sites. We found that the luminescence intensities were significantly reduced by transfection with *miR-26a* or *miR-26b* and vectors carrying the wild-type 3′-UTR of *LOXL2*, whereas transfection with deletion vectors blocked the decrease in luminescence. These data suggested that *miR-26a* or *miR-26b* bound directly to specific sites in the 3′-UTR of *LOXL2* ([Fig. 3C and D](#f3-ijo-48-05-1837){ref-type="fig"}).

We also found that the mRNA and protein expression levels of *PLOD2/*PLOD2 were significantly repressed in *miR-26a* or *miR-26b* transfectant cells in comparison with mock or miR-control transfectants ([Fig. 4A and B](#f4-ijo-48-05-1837){ref-type="fig"}). We also observed that the luminescence intensities were significantly reduced by transfection with *miR-26a* or *miR-26b* and vectors carrying the wild-type 3′-UTR of *PLOD2*, whereas transfection with deletion vectors blocked the decrease in luminescence. These data suggested that *miR-26a* or *miR-26b* bound directly to specific sites in the 3′-UTR of *PLOD2* ([Fig. 4C and D](#f4-ijo-48-05-1837){ref-type="fig"}).

Silencing PLOD2 affected cell proliferation, migration and invasion activities in ccRCC cells
---------------------------------------------------------------------------------------------

We recently presented a loss-of-function study of *LOXL2* in RCC cells (786-O and A498) by using two siRNAs (786-O and A498) ([@b12-ijo-48-05-1837]). Those data showed that the silencing of *LOXL2* significantly suppressed cancer cell migration and invasion activities in RCC cells.

To investigate the functional role of *PLOD2* in ccRCC cells, we performed a loss-of-function study using *si-PLOD2* transfected cells. First, we evaluated the knockdown efficiency of *si-PLOD2* transfection in 786-O and A498 cells. qRT-PCR and western blotting indicated that *si-PLOD2* transfection effectively downregulated *PLOD2* expression in both cell lines (786-O, P\<0.0001; A498, P\<0.0001; [Fig. 5A and B](#f5-ijo-48-05-1837){ref-type="fig"}).

The XTT assay demonstrated that cell proliferation was not inhibited significantly in *si-PLOD2* transfectant cells in comparison with the mock or negative control transfectants ([Fig. 5C](#f5-ijo-48-05-1837){ref-type="fig"}).

In contrast, the migration assay demonstrated that cell migration activity was significantly inhibited in *si-PLOD2* transfectants in comparison with the mock or negative control transfectants ([Fig. 5D](#f5-ijo-48-05-1837){ref-type="fig"}). The Matrigel invasion assay demonstrated that invasive activity was significantly inhibited in *si-PLOD2* transfectants in comparison with the mock or negative control transfectants ([Fig. 5E](#f5-ijo-48-05-1837){ref-type="fig"}).

Expression of LOXL2 and PLOD2 in ccRCC clinical specimens
---------------------------------------------------------

A total of 15 pairs of ccRCC specimens and corresponding non-cancerous specimens were used for expression studies of *LOXL2* and *PLOD2* using RT-PCR. We showed that *LOXL2* and *PLOD2* were significantly upregulated in cancer tissues compared with normal tissues (P=0.0001 and P\<0.0001, respectively; [Fig. 6A and B](#f6-ijo-48-05-1837){ref-type="fig"}). Furthermore, Spearman\'s rank test showed a negative correlation between the expression of *miR-26a/PLOD2* and *miR-26b/PLOD2* ([Fig. 6E and F](#f6-ijo-48-05-1837){ref-type="fig"}).

Discussion
==========

A growing body of evidence has shown that aberrantly expressed miRNAs can disrupt tightly regulated RNA networks in cancer cells and promote human oncogenesis and metastasis ([@b7-ijo-48-05-1837],[@b9-ijo-48-05-1837],[@b24-ijo-48-05-1837]--[@b26-ijo-48-05-1837]). Recently, our studies identified a variety of novel RCC molecular pathways regulated by tumor-suppressive miRNAs ([@b12-ijo-48-05-1837]--[@b15-ijo-48-05-1837]). In the present study, we focused on *miR-26a* and *miR-26b* because the expression levels of these miRNAs were reduced in the miRNA signatures of various types of cancers ([@b10-ijo-48-05-1837],[@b18-ijo-48-05-1837],[@b19-ijo-48-05-1837],[@b27-ijo-48-05-1837]). Moreover, the functional roles of these miRNAs in RCC cells are not clear. Our present data showed that *miR-26a* and *miR-26b* act as tumor suppressors that modulate cancer cell migration and invasion in RCC cells. Our previous studies of oral cancer and prostate cancer demonstrated the tumor-suppressive roles of these miRNAs ([@b19-ijo-48-05-1837],[@b20-ijo-48-05-1837]), and those findings support the present results obtained with RCC cells. Downregulation and tumor-suppressive roles of *miR-26a* or *miR-26b* have been reported in several types of cancer, such as bladder, breast, hepatocellular carcinoma and oral cancer ([@b19-ijo-48-05-1837],[@b28-ijo-48-05-1837]--[@b30-ijo-48-05-1837]).

In the human genome, the *miR-26* family consists of three subtypes of miRNAs: *miR-26a-1*, *miR-26a-2* and *miR-26b*. The mature sequences of *miR-26a-1* and *miR-26a-2* are identical, whereas the two nucleotides differ from that of *miR-26b* (miRBase release 21; <http://www.mirbase.org/>). The molecular mechanisms responsible for silencing the expression of the *miR-26* family are still unclear. A recent study indicated that MYC oncogene directly bound to the promoter regions of *miR-26a-1*, *miR-26a-2* and *miR-26b* and negatively regulated expression of these miRNAs in prostate cancer cells ([@b31-ijo-48-05-1837]). Overexpression of *MYC* was observed in RCC clinical specimens ([@b15-ijo-48-05-1837],[@b32-ijo-48-05-1837]), suggesting *MYC* might be a mediator for expression control of tumor-suppressive miRNAs in cancer cells.

A single miRNA may regulate multiple protein-coding genes; indeed, bioinformatics studies have shown that miRNAs regulate \>30--60% of the protein-coding genes in the human genome ([@b7-ijo-48-05-1837],[@b33-ijo-48-05-1837]). Reduced expression of tumor-suppressive miRNAs may cause overexpression of oncogenic genes in cancer cells. To better understand RCC oncogenesis and metastasis, we identified *miR-26a* and *miR-26b* target genes using *in silico* analysis. Recent miRNA studies in our laboratory have utilized this strategy to identify novel molecular targets and pathways regulated by tumor-suppressive miRNAs in several cancers, including RCC ([@b12-ijo-48-05-1837],[@b20-ijo-48-05-1837]).

A total of 39 putative target genes of *miR-26a* and *miR-26b* were identified in the present study. Among these genes, we focused on *LOXL2* and *PLOD2* because they function as collagen cross-linking enzymes. Numerous studies have shown that aberrant expression of collagen cross-linking enzymes promotes extracellular matrix (ECM) stiffening, resulting in enhanced cancer cell migration and invasion ([@b22-ijo-48-05-1837],[@b34-ijo-48-05-1837]--[@b39-ijo-48-05-1837]). Overexpression of ECM components has been observed in several cancers ([@b21-ijo-48-05-1837],[@b23-ijo-48-05-1837],[@b40-ijo-48-05-1837]). Recently, a number of studies indicated that several miRNAs regulated ECM component genes, and aberrantly expressed miRNAs have contributed to cancer cell progression by dysregulation of cell adhesion, polarity and ECM remodeling ([@b21-ijo-48-05-1837],[@b23-ijo-48-05-1837]). Our past studies found that the tumor-suppressive *miR-29*-family (*miR-29a*, *miR-29b* and *miR-29c*) and *miR-218* directly regulated laminins (*LAMC2* and *LAMB3*) and integrins (*ITGA6* and *ITGB3*), such that restoration of these miRNAs inhibited cancer cell migration and invasion ([@b21-ijo-48-05-1837],[@b41-ijo-48-05-1837],[@b42-ijo-48-05-1837]).

Once collagen is secreted, collagen cross-linking occurs on lysine and hydroxylysine residues by the lysyl oxidase (LOX) family of enzymes ([@b22-ijo-48-05-1837],[@b43-ijo-48-05-1837]). More recently, we showed that the *miR-29s*-family directly targeted *LOXL2* in RCC and lung cancers ([@b12-ijo-48-05-1837]). Overexpression of *LOXL2* was observed in RCC clinical specimens and silencing of *LOXL2* inhibited cancer cell migration and invasion in ccRCC cell lines ([@b12-ijo-48-05-1837]). Other research groups found that increased expression of *LOXL2* is correlated with disease progression, including RCC ([@b34-ijo-48-05-1837],[@b44-ijo-48-05-1837]). The function of the LOX-family is covalent crosslinking of collagen and/or elastin in the ECM ([@b35-ijo-48-05-1837],[@b36-ijo-48-05-1837]). Aberrant expression of LOX-family proteins has been reported in several diseases, including cancers ([@b34-ijo-48-05-1837]--[@b39-ijo-48-05-1837]). Interestingly, *LOXL2* is a direct transcriptional target of HIF-1. Moreover, nuclear LOXL2 interacts with transcription factor SNAIL1 and represses E-cadherin as well as induces EMT ([@b45-ijo-48-05-1837],[@b46-ijo-48-05-1837]). In this study, we demonstrated direct regulation of *LOXL2* by *miR-26a* and *miR-26b* in RCC cells as observed with the *miR-29s*-family. These findings showed that tumor-suppressive *miR-26a/b-LOXL2* is the pivotal pathway contributing to cancer cell migration and invasion in RCC.

In this study, we also focused on the *PLOD2* (procollagen-lysine 2-oxyglutarate-dioxygenase) gene as a target of *miR-26a* and *miR-26b* and demonstrated the direct regulation of these miRNAs by luciferase reporter assays. *PLOD2* encodes an enzyme that mediates collagen lysine hydroxylation. Collagen cross-linking that are derived from hydroxylated lysine residues have increased stability compared with non-hydroxylated lysine residues ([@b22-ijo-48-05-1837],[@b47-ijo-48-05-1837]). Overexpression of *PLOD2* in ccRCC clinical specimens and promoting migration and invasion in cancer cells were observed in the present study. In breast cancer, Kaplan-Meier curves of disease-specific survival stratified by *PLOD2* expression revealed that high *PLOD2* expression was significantly associated with decreased disease-specific survival ([@b48-ijo-48-05-1837]). Moreover, *PLOD2* expression promoted tumor stiffness and was required for metastasis to lymph nodes and lungs ([@b22-ijo-48-05-1837],[@b48-ijo-48-05-1837]).

In conclusion, *miR-26a* and *miR-26b* were significantly downregulated in ccRCC clinical specimens and appeared to function as tumor suppressors through regulation of collagen cross-linking enzymes, *LOXL2* and *PLOD2*, both of which function as oncogenes in this disease. The identification of novel molecular targets and pathways regulated by the tumor-suppressive *miR-26a* and *miR-26b* may lead to a better understanding of ccRCC and the development of new therapeutic strategies to treat this disease.
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![Expression levels of *miR-26a* and *miR-26b* in ccRCC clinical specimens and cell lines 786-O and A498. (A and B) Quantitative real-time RT-PCR showed that the expression levels of *miR-26a* and *miR-26b* were significantly lower in ccRCC tissues and RCC cell lines than in normal kidney tissues. *RNU48* was used as an internal control. (C--E) Effects of *miR-26a* or *miR-26b* transfection on RCC cell lines 786-O and A498. (C) Cell proliferation was determined by XTT assays 72 h after transfection with *miR-26a* or *miR-26b* (10 nM). (D) Cell migration activity was determined by wound-healing assays 48 h after transfection with *miR-26a* or *miR-26b* (10 nM). (E) Cell invasion activity was determined by Matrigel invasion assays 48 h after transfection with *miR-26a* or *miR-26b* (10 nM). ^\*^P\<0.001.](IJO-48-05-1837-g00){#f1-ijo-48-05-1837}

![Strategy for selecting target genes regulated by *miR-26a* and *miR-26b* in RCC cells.](IJO-48-05-1837-g01){#f2-ijo-48-05-1837}

![Expression of the gene encoding *LOXL2* is suppressed by transfection of RCC cell lines 786-O and A498 with *miR-26a* or *miR-26b*. (A) *LOXL2* mRNA expression was evaluated by quantitative RT-PCR 72 h after transfection with *miR-26a* or *miR-26b* (10 nM). *GUSB* was used as an internal control. ^\*^P\<0.01. (B) LOXL2 protein expression was evaluated by western blotting 72 h after transfection with *miR-26a* or *miR-26b* (10 nM). GAPDH was used as a loading control. (C) *miR-26a* and *miR-26b* binding sites in the 3′-UTR of *LOXL2* mRNA. (D) Luciferase reporter assays in A498 cells using vectors encoding putative *miR-26a* and *miR-26b* target sites at position 456-462 and 828-835 of the *LOXL2* 3′-UTR. *Renilla* luciferase values were normalized to firefly luciferase values. ^\*^P\<0.0001.](IJO-48-05-1837-g02){#f3-ijo-48-05-1837}

![Expression of the gene encoding *PLOD2* is suppressed by transfection of RCC cell lines 786-O and A498 with *miR-26a* or *miR-26b*. (A) *PLOD2* mRNA expression was evaluated by quantitative RT-PCR 72 h after transfection with *miR-26a* or *miR-26b* (10 nM). *GUSB* was used as an internal control. ^\*^P\<0.01. (B) PLOD2 protein expression was evaluated by western blotting 72 h after transfection with *miR-26a* or *miR-26b* (10 nM). GAPDH was used as a loading control. (C) *miR-26a* and *miR-26b* binding site in the 3′-UTR of *PLOD2* mRNA. (D) Luciferase reporter assays in A498 cells using a vector encoding a putative *miR-26a* and *miR-26b* target sites at position 905-912 and 1188-1194 of the *PLOD2* 3′-UTR. *Renilla* luciferase values were normalized to firefly luciferase values. ^\*^P\<0.0001.](IJO-48-05-1837-g03){#f4-ijo-48-05-1837}

![Effects on RCC cell proliferation, migration and invasion after silencing of *PLOD2* mRNA and protein expression with *si-PLOD2* transfection. (A) *PLOD2* mRNA expression levels were evaluated by quantitative RT-PCR 72 h after transfection with *si-PLOD2* (10 nM). *GUSB* was used as an internal control. ^\*^P\<0.0001. (B) PLOD2 protein expression levels were evaluated by western blotting 72 h after transfection with *si-PLOD2* (10 nM). GAPDH was used as a loading control. (C) Cell proliferation was determined by XTT assays. (D) Cell migration activity was determined by wound-healing assays. (E) Cell invasion activity was determined by Matrigel invasion assays. ^\*^P\<0.0001.](IJO-48-05-1837-g04){#f5-ijo-48-05-1837}

![Expression levels of *LOXL2* and *PLOD2* in ccRCC clinical specimens and cell lines 786-O and A498. (A and B) Quantitative real-time RT-PCR showed that the expression levels of *LOXL2* and *PLOD2* were significantly higher in ccRCC tissues and RCC cell lines than in normal kidney tissues. *GUSB* was used as an internal control. (C and D) Correlations between *LOXL2-miR-26a* expression or *LOXL2-miR-26b* expression were determined in RCC clinical specimens. (E and F) Correlations between *PLOD2-miR-26a* expression or *PLOD2-miR-26b* expression were determined in RCC clinical specimens.](IJO-48-05-1837-g05){#f6-ijo-48-05-1837}

###### 

Characteristics of ccRCC clinical specimens.

  No.   Pathology    Grade          pT    INF   v   ly   eg or ig   fc   im   rc   rp   s
  ----- ------------ -------------- ----- ----- --- ---- ---------- ---- ---- ---- ---- ---
  1     Clear cell   G2             T1a   a     0   0    eg         1    0    0    0    0
  2     Clear cell   G1\>G2         T1a   a     0   0    eg         1    0    0    0    0
  3     Clear cell   G3\>G2         T1b   a     0   0    eg         1    0    0    0    0
  4     Clear cell   G2\>G3\>G1     T1a   a     0   0    eg         1    0    0    0    0
  5     Clear cell   G2\>G3         T1b   a     0   0    eg         1    1    0    0    0
  6     Clear cell   G2\>G3         T3a   a     1   0    eg         1    0    0    0    0
  7     Clear cell   G2\>G3\>G1     T3a   b     1   0    ig         0    1    1    0    0
  8     Clear cell   G2\>G3\>G1     T3a   b     1   0    ig         1    0    0    0    0
  9     Clear cell   G3             T3a   b     1   0    ig         0    0    0    0    0
  10    Clear cell   G1\>G2         T1b   a     0   0    eg         1    0    0    0    0
  11    Clear cell   G2\>G1\>G3     T3a   b     1   0    ig         0    0    0    0    0
  12    Clear cell   G2             T1a   a     0   0    eg         0    0    0    0    0
  13    Clear cell   G2\>G1\>\>G3   T1b   b     0   0    eg         1    0    0    0    0
  14    Clear cell   G2\>G1         T1a   b     0   0    eg         1    0    0    0    0
  15    Clear cell   G2             T1b   a     0   0    eg         0    0    0    0    0

INF, infiltration; v, vein; ly, lymph node; eg, expansive growth; ig, infiltrative growth; fc, capsular formation; im, intrarenal metastasis; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion.

###### 

Putative candidate target genes regulated by *miR-26a* and *miR-26b* in RCC cells.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez gene ID   Symbol       Gene name                                                                                  Location       No. of conserved target sites   No. of poorly conserved target sites   GEO (GSE36895, GSE22541 average fold-change
  ---------------- ------------ ------------------------------------------------------------------------------------------ -------------- ------------------------------- -------------------------------------- ---------------------------------------------
  5352             *PLOD2*      Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2                                         3q24           2                               0                                      2.2220507

  4017             *LOXL2*      Lysyl oxidase-like 2                                                                       8p21.3         2                               0                                      2.7719142

  2146             *EZH2*       Enhancer of zeste homolog 2 (*Drosophil*a)                                                 7q35-q36       1                               0                                      2.0032272

  3625             *INHBB*      Inhibin, β B                                                                               2cen-q13       1                               0                                      3.7558112

  3678             *ITGA5*      Integrin, α 5 (fibronectin receptor, α polypeptide)                                        12q11-q13      1                               0                                      2.8391342

  23023            *TMCC1*      Transmembrane and coiled-coil domain family 1                                              3q22.1         1                               1                                      2.226072

  1404             *HAPLN1*     Hyaluronan and proteoglycan link protein 1                                                 5q14.3         1                               1                                      2.7813237

  7903             *ST8SIA4*    ST8 α-N-acetyl-neuraminide\                                                                5q21           1                               0                                      3.1741676
                                α-2,8-sialyltransferase 4                                                                                                                                                        

  1846             *DUSP4*      Dual specificity phosphatase 4                                                             8p12-p11       1                               0                                      2.1518986

  6890             *TAP1*       Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)                                6p21.3         0                               1                                      2.0403051

  7272             *TTK*        TTK protein kinase                                                                         6q14.1         0                               1                                      2.3837836

  170384           *FUT11*      Fucosyltransferase 11 (α (1,3) fucosyltransferase)                                         10q22.2        0                               1                                      2.0443428

  22974            *TPX2*       TPX2, microtubule-associated, homolog (*Xenopus laevis*)                                   20q11.2        0                               1                                      2.662108

  2210             *FCGR1B*     Fc fragment of IgG, high affinity Ib, receptor (CD64)                                      1p11.2         0                               1                                      2.294377

  4747             *NEFL*       Neurofilament, light polypeptide                                                           8p21           0                               1                                      2.1319628

  5836             *PYGL*       Phosphorylase, glycogen, liver                                                             14q21-q22      0                               1                                      2.0643747

  1234             *CCR5*       Chemokine (C-C motif) receptor 5                                                           3p21.31        0                               1                                      3.3846455

  55165            *CEP55*      Centrosomal protein 55 kDa                                                                 10q23.33       0                               1                                      2.0711598

  10288            *LILRB2*     Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2   19q13.4        0                               1                                      2.454539

  1356             *CP*         Ceruloplasmin (ferroxidase)                                                                3q23-q25       0                               1                                      3.9467278

  3910             *LAMA4*      Laminin, α 4                                                                               6q21           0                               1                                      2.2182174

  163404           *LPPR5*      Lipid phosphate phosphatase-related protein type 5                                         1p21.3         0                               1                                      2.450066

  5027             *P2RX7*      Purinergic receptor P2X, ligand-gated ion channel, 7                                       12q24          0                               3                                      3.0084689

  330              *BIRC3*      Baculoviral IAP repeat containing 3                                                        11q22          0                               1                                      2.2927191

  6507             *SLC1A3*     Solute carrier family 1 (glial high affinity glutamate transporter), member 3              5p13           0                               1                                      2.1052346

  2335             *FN1*        Fibronectin 1                                                                              2q34           0                               1                                      2.4469628

  8701             *DNAH11*     Dynein, axonemal, heavy chain 11                                                           7p21           0                               1                                      2.2785249

  79850            *FAM57A*     Family with sequence similarity 57, member A                                               17p13.3        0                               1                                      2.2900116

  1462             *VCAN*       Versican                                                                                   5q14.3         0                               1                                      2.524361

  128346           *C1orf162*   Chromosome 1 open reading frame 162                                                        1p13.2         0                               1                                      2.2255776

  4015             *LOX*        Lysyl oxidase                                                                              5q23.2         0                               1                                      3.3194032

  115761           *ARL11*      ADP-ribosylation factor-like 11                                                            13q14.2        0                               1                                      2.4013827

  286336           *FAM78A*     Family with sequence similarity 78, member A                                               9q34           0                               1                                      2.1942985

  6664             *SOX11*      SRY (sex determining region Y)-box 11                                                      2p25           0                               1                                      2.577679

  9770             *RASSF2*     Ras association (RalGDS/AF-6) domain family member 2                                       20p13          0                               1                                      2.619857

  57823            *SLAMF7*     SLAM family member 7                                                                       1q23.1-q24.1   0                               1                                      2.063896

  58475            *MS4A7*      Membrane-spanning 4-domains, subfamily A, member 7                                         11q12          0                               1                                      2.0315962

  79742            *CXorf36*    Chromosome X open reading frame 36                                                         Xp11.3         0                               1                                      2.3148956

  146857           *SLFN13*     Schlafen family member 13                                                                  17q12          0                               1                                      2.6972997
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Contributed equally
